Tuesday, February 20, 2018 -- A new study finds that a psoriasis drug might help to reduce heart disease risk. Overall, it reduced a particular risk marker by 19 percent.
Monday, February 19, 2018 -- Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.
Monday, February 19, 2018 -- Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals. The new findings presented over the weekend show the drug can maintain quality of life in the long term and clear nasty scalp plaques. Cosen...
Tuesday, February 20, 2018 -- NewsNew data from the VOYAGE 2 trial shows high efficacy response rates were achieved with continuous Tremfya (guselkumab) treatment versus withdrawal. The results were reported over the weekend in San Diego.Contributed Author: Janssen Pharmaceuticals, Inc.Topics: Drug Development
Tuesday, February 20, 2018 -- Eli Lilly and Company reported that Taltz (ixekizumab) in a phase 3b trial has helped patients with moderate-to-severe genital psoriasis in significantly reducing the impact of their condition on sexual activity.
Tuesday, February 20, 2018 -- (MENAFN Editorial) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / February 20, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that its licensee Janssen Resea...
Sunday, February 18, 2018 -- (MedPage Today) -- Agent may also option in patients who withdrew from therapy and were re-treated
Tuesday, February 20, 2018 -- (MedPage Today) -- Outcomes didn't differ in randomized trial